New blood thinner may shield heart during artery procedure

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria : * Stable coronary patient, or patient presenting with a non ST-elevation acute coronary syndrome without troponin elevation, or with troponin back to normal, * Patient treated with a combination of Aspirin + Clopidogrel before hospitalization at the study center, * Patient with at least one highly calcified coronary lesion eligible for rotational atherectomy prior to angioplasty, * Patient agreed to participate after full information on the study. Exclusion criteria : * Acute coronary syndrome with ST-elevation, * Plasma troponin level higher than 3 times the upper limit of the laboratory, * Lesion located on a coronary bypass, * Coronary thrombus diagnosed by angiography, * Coronary dissection diagnosed by angiography, * Left ventricular ejection fraction lower than 30%, * Contra-indication to use Ticagrelor or Clopidogrel as listed in the Summary of Product Characteristics (SmPC, annex 1 \& 2): * Known hypersensitivity to the active substance or to the excipients, * Active pathological bleeding, * History of intracranial hemorrhage, * Moderate to severe hepatic impairment, * Co-administration with a strong cytochrome P450 3A4 inhibitor (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir), * Other conditions at increased risk of bleeding: * Congenital or acquired coagulation disorder * Gastroduodenal bleeding within past 6 months, * Recent major trauma or surgery within past 30 days, * Concomitant use of fibrinolytics, oral anticoagulation, non-steroidal antiinflammatory drugs, * Significant anemia, * Increased risk of bradycardia, * History of asthma or Chronic Obstructive Pulmonary Disease, * Uric acid nephropathy, * Ischemic stroke within 7 days, * Heredity galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, * Concomitant use of a strong CYP3A4 inducer * Concomitant use of CYP3A4 substrates with narrow therapeutic indices (e.g. cisapride, ergot alkaloids), simvastatin at a dose greater than 40 mg/d, * Concomitant use of Selective Serotonin Reuptake inhibitors, * Concomitant use of digoxin without close clinical and laboratory monitoring, * Contra-indication to use Aspirin, * Breast-feeding, * Pregnancy, * Adult protected by the law, * Patient participating in another biomedical research.